441 related articles for article (PubMed ID: 25045248)
1. Design of oral agents for the management of multiple sclerosis: benefit and risk assessment for dimethyl fumarate.
Nicholas JA; Boster AL; Imitola J; O'Connell C; Racke MK
Drug Des Devel Ther; 2014; 8():897-908. PubMed ID: 25045248
[TBL] [Abstract][Full Text] [Related]
2. Efficacy and Safety of Delayed-release Dimethyl Fumarate for Relapsing-remitting Multiple Sclerosis in Prior Interferon Users: An Integrated Analysis of DEFINE and CONFIRM.
Fernández Ó; Giovannoni G; Fox RJ; Gold R; Phillips JT; Potts J; Okwuokenye M; Marantz JL
Clin Ther; 2017 Aug; 39(8):1671-1679. PubMed ID: 28751099
[TBL] [Abstract][Full Text] [Related]
3. An evaluation of dimethyl fumarate for the treatment of relapsing remitting multiple sclerosis.
Valencia-Sanchez C; Carter JL
Expert Opin Pharmacother; 2020 Aug; 21(12):1399-1405. PubMed ID: 32543241
[TBL] [Abstract][Full Text] [Related]
4. Medication adherence and health outcomes in persons with multiple sclerosis treated with dimethyl fumarate.
Jožef M; Locatelli I; Brecl Jakob G; Rot U; Kos M
Mult Scler Relat Disord; 2023 Apr; 72():104615. PubMed ID: 36933300
[TBL] [Abstract][Full Text] [Related]
5. Safety and efficacy of dimethyl fumarate in multiple sclerosis: a multi-center observational study.
Miclea A; Leussink VI; Hartung HP; Gold R; Hoepner R
J Neurol; 2016 Aug; 263(8):1626-32. PubMed ID: 27260297
[TBL] [Abstract][Full Text] [Related]
6. Comparative effectiveness using a matching-adjusted indirect comparison between delayed-release dimethyl fumarate and fingolimod for the treatment of multiple sclerosis.
Fox RJ; Chan A; Zhang A; Xiao J; Levison D; Lewin JB; Edwards MR; Marantz JL
Curr Med Res Opin; 2017 Feb; 33(2):175-183. PubMed ID: 27733070
[TBL] [Abstract][Full Text] [Related]
7. Cost-effectiveness of delayed-release dimethyl fumarate for the treatment of relapsing forms of multiple sclerosis in the United States.
Mauskopf J; Fay M; Iyer R; Sarda S; Livingston T
J Med Econ; 2016; 19(4):432-42. PubMed ID: 26707273
[TBL] [Abstract][Full Text] [Related]
8. Diroximel fumarate to treat multiple sclerosis.
Wang Y; Bhargava P
Drugs Today (Barc); 2020 Jul; 56(7):431-437. PubMed ID: 32648853
[TBL] [Abstract][Full Text] [Related]
9. Dimethyl fumarate treatment in multiple sclerosis: Recent advances in clinical and immunological studies.
Montes Diaz G; Hupperts R; Fraussen J; Somers V
Autoimmun Rev; 2018 Dec; 17(12):1240-1250. PubMed ID: 30316988
[TBL] [Abstract][Full Text] [Related]
10. Comparative effectiveness of teriflunomide and dimethyl fumarate in patients with relapsing forms of MS in the retrospective real-world Teri-RADAR study.
Zivadinov R; Kresa-Reahl K; Weinstock-Guttman B; Edwards K; Burudpakdee C; Bergsland N; Dwyer MG; Khatri B; Thangavelu K; Chavin J; Mandel M; Cohan S
J Comp Eff Res; 2019 Apr; 8(5):305-316. PubMed ID: 30754997
[TBL] [Abstract][Full Text] [Related]
11. Diroximel fumarate in the treatment of multiple sclerosis.
Jonasson E; Sejbaek T
Neurodegener Dis Manag; 2020 Oct; 10(5):267-276. PubMed ID: 32686599
[TBL] [Abstract][Full Text] [Related]
12. Relapses Requiring Intravenous Steroid Use and Multiple-Sclerosis-related Hospitalizations: Integrated Analysis of the Delayed-release Dimethyl Fumarate Phase III Studies.
Giovannoni G; Gold R; Fox RJ; Kappos L; Kita M; Yang M; Sarda SP; Zhang R; Viglietta V; Havrdova E
Clin Ther; 2015 Nov; 37(11):2543-51. PubMed ID: 26526385
[TBL] [Abstract][Full Text] [Related]
13. Long-term safety and efficacy of dimethyl fumarate for up to 13 years in patients with relapsing-remitting multiple sclerosis: Final ENDORSE study results.
Gold R; Arnold DL; Bar-Or A; Fox RJ; Kappos L; Mokliatchouk O; Jiang X; Lyons J; Kapadia S; Miller C
Mult Scler; 2022 Apr; 28(5):801-816. PubMed ID: 34465252
[TBL] [Abstract][Full Text] [Related]
14. Long-term effects of delayed-release dimethyl fumarate in multiple sclerosis: Interim analysis of ENDORSE, a randomized extension study.
Gold R; Arnold DL; Bar-Or A; Hutchinson M; Kappos L; Havrdova E; MacManus DG; Yousry TA; Pozzilli C; Selmaj K; Sweetser MT; Zhang R; Yang M; Potts J; Novas M; Miller DH; Kurukulasuriya NC; Fox RJ; Phillips TJ
Mult Scler; 2017 Feb; 23(2):253-265. PubMed ID: 27207449
[TBL] [Abstract][Full Text] [Related]
15. Comparative efficacy and discontinuation of dimethyl fumarate and fingolimod in clinical practice at 12-month follow-up.
Hersh CM; Love TE; Cohn S; Hara-Cleaver C; Bermel RA; Fox RJ; Cohen JA; Ontaneda D
Mult Scler Relat Disord; 2016 Nov; 10():44-52. PubMed ID: 27919497
[TBL] [Abstract][Full Text] [Related]
16. The Use of Oral Disease-Modifying Therapies in Multiple Sclerosis.
Kretzschmar B; Pellkofer H; Weber MS
Curr Neurol Neurosci Rep; 2016 Apr; 16(4):38. PubMed ID: 26944956
[TBL] [Abstract][Full Text] [Related]
17. Comparing outcomes from clinical studies of oral disease-modifying therapies (dimethyl fumarate, fingolimod, and teriflunomide) in relapsing MS: Assessing absolute differences using a number needed to treat analysis.
Freedman MS; Montalban X; Miller AE; Dive-Pouletty C; Hass S; Thangavelu K; Leist TP
Mult Scler Relat Disord; 2016 Nov; 10():204-212. PubMed ID: 27919491
[TBL] [Abstract][Full Text] [Related]
18. Comparative effectiveness of dimethyl fumarate versus fingolimod and teriflunomide among MS patients switching from first-generation platform therapies in the US.
Ontaneda D; Nicholas J; Carraro M; Zhou J; Hou Q; Babb J; Riester K; Mendoza JP; Livingston T; Jhaveri M
Mult Scler Relat Disord; 2019 Jan; 27():101-111. PubMed ID: 30368221
[TBL] [Abstract][Full Text] [Related]
19. Dimethyl Fumarate: A Review in Moderate to Severe Plaque Psoriasis.
Blair HA
Drugs; 2018 Jan; 78(1):123-130. PubMed ID: 29236231
[TBL] [Abstract][Full Text] [Related]
20. Role of dimethyl fumarate in oxidative stress of multiple sclerosis: A review.
Suneetha A; Raja Rajeswari K
J Chromatogr B Analyt Technol Biomed Life Sci; 2016 Apr; 1019():15-20. PubMed ID: 26899449
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
